|
Coronary Arteriosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The objective was to assess the relationship of LTA gene, LGALS2 gene and coronary artery disease, using a meta-analysis.
|
19726041 |
2010 |
|
Coronary Artery Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The objective was to assess the relationship of LTA gene, LGALS2 gene and coronary artery disease, using a meta-analysis.
|
19726041 |
2010 |
|
Coronary Arteriosclerosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, the polymorphism of LGALS2 was not associated with the severity of coronary atherosclerosis.
|
17493152 |
2007 |
|
Coronary Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease.
|
17040205 |
2007 |
|
Coronary Artery Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease.
|
17040205 |
2007 |
|
Coronary heart disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, the PPARG×AGTR1×CXCL16×LGALS2 model was associated with CHD susceptibility (OR=3.97, 95% CI=2.01-7.84).
|
26045830 |
2015 |
|
Coronary heart disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Galectin-2 is a monocyte-expressed carbohydrate-binding lectin, for which increased expression is genetically determined and associated with decreased collateral arteriogenesis in obstructive coronary artery disease patients.
|
25884209 |
2015 |
|
Coronary heart disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The objective was to assess the relationship of LTA gene, LGALS2 gene and coronary artery disease, using a meta-analysis.
|
19726041 |
2010 |
|
Coronary heart disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease.
|
17040205 |
2007 |
|
Ischemic stroke
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genetic variation in the lymphotoxin-alpha cascade (LTA, LGALS2, and PSMA6) is not a major risk factor for IS.
|
19182073 |
2009 |
|
Ischemic stroke
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we examined whether the LGALS2 3279TT homozygote variant alone can influence the prevalence of ischaemic stroke, and whether it can interact somehow with the disadvantageous LTA 252GG homozygote variant.
|
19013708 |
2009 |
|
Ischemic stroke
|
0.030 |
Biomarker
|
disease |
BEFREE |
Four new susceptibility genes have been identified using genome-wide association studies or genome-wide linkage studies: LTA (encoding cytokine lymphotoxin-alpha) on 6p21.3 for MI; LGALS2 (encoding galectin-2, an LTA-interacting protein) on 22q12-q13 for MI; ALOX5AP (encoding 5-lipoxygenase activating protein involved in synthesizing potent pro-inflammatory leukotrienes) on 13q12-13 for MI and stroke; and PDE4D (encoding phosphodiesterase 4D) on 5q12 for ischemic stroke.
|
15811259 |
2005 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Further studies are required to replicate the potential association of LGALS2 3279 C/T with DBP, and examine whether this SNP could be used as a marker of increased risk for future cardiovascular events in RA populations.
|
19330599 |
2009 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Although hypertension, a very prevalent entity in rheumatoid arthritis (RA), is one of the greatest risk factors for MI, the possible association of LGALS2 3279 C/T and hypertension has not been investigated.
|
19330599 |
2009 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The frequency of LGALS2 polymorphisms was similar between RA and controls and was not associated with CVD among patients with RA.
|
18230628 |
2008 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The Chi-square test, multivariable logistic regression analysis with adjustment for age, sex, body mass index, and the prevalence of hypertension, hypercholesterolemia, and diabetes mellitus, as well as a stepwise forward selection procedure revealed that the 2445G-->A (Ala54Thr) polymorphism (rs1799883) of FABP2, the -108/3G-->4G polymorphism of IPF1 (S82168), the A-->G (rs2241883" genes_norm="2168">Thr94Ala) polymorphism (rs2241883) of FABP1, the G-->A (rs529038" genes_norm="6098">Asp2213Asn) polymorphism (rs529038) of ROS1, the -11377C-->G polymorphism (rs266729) of ADIPOQ, the 162A-->C polymorphism (rs4769055) of ALOX5AP, the -786T-->C polymorphism (rs2070744) of NOS3, and the 3279C-->T polymorphism (rs7291467) of LGALS2 were associated (P<0.05) with the prevalence of atherothrombotic cerebral infarction.
|
18506375 |
2008 |
|
Metabolic Syndrome X
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that FABP2, IPF1, FABP1, ROS1, ADIPOQ, ALOX5AP, NOS3, and LGALS2 are susceptibility loci for atherothrombotic cerebral infarction among Japanese individuals with metabolic syndrome.
|
18506375 |
2008 |
|
Metabolic Syndrome X
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In this study, we used the galectin 2 (LGALS2) genotype, which affects LTA secretion but is located on another chromosome than the HLA gene cluster or TNF, to examine the relationship between the LTA pathway and traits of the metabolic syndrome.
|
16468038 |
2006 |
|
Filariasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studies confirm the functionality of BmLec-2 and indicate anti-Lec-2 antibody responses are common in persons with filariasis.
|
31738955 |
2020 |
|
Angiostrongyliasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Application of Recombinant <i>Angiostrongylus cantonensis</i> Galectin-2 Protein for Serodiagnosis of Human Angiostrongyliasis by Immunoblotting.
|
31392957 |
2019 |
|
Angiostrongylus Infections
|
0.010 |
Biomarker
|
disease |
BEFREE |
Application of Recombinant <i>Angiostrongylus cantonensis</i> Galectin-2 Protein for Serodiagnosis of Human Angiostrongyliasis by Immunoblotting.
|
31392957 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have confirmed the involvement of specific proteins previously associated with ALS (Galectin 2 (<i>LGALS3</i>), Transthyretin (<i>TTR</i>), Protein S100-A6 (<i>S100A6</i>), and Protein S100-A11 (<i>S100A11</i>)) and have shown the involvement of proteins not previously described in the ALS context (Methanethiol oxidase (<i>SELENBP1</i>), Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (<i>PIN-1</i>), Calcyclin-binding protein (<i>CACYBP</i>) and Rho-associated protein kinase 2 (<i>ROCK2</i>)).
|
30577465 |
2018 |
|
Fetal Growth Retardation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There are significant gender-specific expression patterns for single prototype galectins with downregulation of gal-2 and gal-13 of male gender placentas in cases of IUGR.
|
27070577 |
2016 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
All the eight mouse galectin genes were expressed in mammary tumors and tumor epithelial cells (TECs), but galectin-2 and -12 were not detected by western analysis in tumors, and galectin-7 was not detected in 60% of the TEC lines.
|
24037315 |
2013 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
The association of low galectin-2 with LNM was found even in early GCs (p = 0.020).
|
22015694 |
2012 |